Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome – Drugs In Development, 2022, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 4, 20 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

1st Bio Therapeutics Inc
Acadia Pharmaceuticals Inc
Adge Pharmaceuticals Inc
Alcyone Therapeutics Inc
Amicus Therapeutics Inc
AMO Pharma Ltd
Ananda Scientific Inc
Anavex Life Sciences Corp
ArmaGen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Connecta Therapeutics SL
CuroNZ Ltd
DepYmed Inc
Echo Pharmaceuticals BV
Epeius Pharma Co
Epigen Biosciences Inc
EuMentis Therapeutics Inc
GEXVal Inc
Herophilus
Jazz Pharmaceuticals Plc
LizarBio Therapeutics Inc
Lucy Therapeutics Inc
Neuren Pharmaceuticals Ltd
Neurogene Inc
Neurolixis Inc
Novartis Gene Therapies
OrganAI AB
PharmatrophiX Inc
Prilenia Therapeutics Development Ltd
Q-State Biosciences Inc
Sarepta Therapeutics Inc
Shape Therapeutics Inc
Starwise Therapeutics LLC
StrideBio Inc
Synaptogenix Inc
Taysha Gene Therapies Inc
Thiogenesis Therapeutics SARL
Ultragenyx Pharmaceutical Inc
Unravel Biosciences
Vaccinex Inc
Vico Therapeutics BV
Vyant Bio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rett Syndrome – Overview

Rett Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rett Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rett Syndrome – Companies Involved in Therapeutics Development

1st Bio Therapeutics Inc

Acadia Pharmaceuticals Inc

Adge Pharmaceuticals Inc

Alcyone Therapeutics Inc

Amicus Therapeutics Inc

AMO Pharma Ltd

Ananda Scientific Inc

Anavex Life Sciences Corp

ArmaGen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioXcel Corp

Connecta Therapeutics SL

CuroNZ Ltd

DepYmed Inc

Echo Pharmaceuticals BV

Epeius Pharma Co

Epigen Biosciences Inc

EuMentis Therapeutics Inc

GEXVal Inc

Herophilus

Jazz Pharmaceuticals Plc

LizarBio Therapeutics Inc

Lucy Therapeutics Inc

Neuren Pharmaceuticals Ltd

Neurogene Inc

Neurolixis Inc

Novartis Gene Therapies

OrganAI AB

PharmatrophiX Inc

Prilenia Therapeutics Development Ltd

Q-State Biosciences Inc

Sarepta Therapeutics Inc

Shape Therapeutics Inc

Starwise Therapeutics LLC

StrideBio Inc

Synaptogenix Inc

Taysha Gene Therapies Inc

Thiogenesis Therapeutics SARL

Ultragenyx Pharmaceutical Inc

Unravel Biosciences

Vaccinex Inc

Vico Therapeutics BV

Vyant Bio Inc

Rett Syndrome – Drug Profiles

1ST-301 – Drug Profile

Product Description

Mechanism Of Action

ACTX-101 – Drug Profile

Product Description

Mechanism Of Action

Antisense Oligonucleotide to Activate MECP2 for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

Astrocytes – Drug Profile

Product Description

Mechanism Of Action

AVXS-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BHV-5000 – Drug Profile

Product Description

Mechanism Of Action

History of Events

blarcamesine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Bryostatin-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BXCL-902 – Drug Profile

Product Description

Mechanism Of Action

cannabidiol – Drug Profile

Product Description

Mechanism Of Action

CTH-120 – Drug Profile

Product Description

Mechanism Of Action

Drugs for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

ECP-012A – Drug Profile

Product Description

Mechanism Of Action

elocalcitol – Drug Profile

Product Description

Mechanism Of Action

History of Events

EM-036 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapies for Angelman Syndrome, Muscular Dystrophy and Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate MECP2 Protein for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

GWP-42006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GXV-001 – Drug Profile

Product Description

Mechanism Of Action

LM-22A4 – Drug Profile

Product Description

Mechanism Of Action

Neurodevelopmental Disease – Drug Profile

Product Description

Mechanism Of Action

NGN-401 – Drug Profile

Product Description

Mechanism Of Action

NLX-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NRP-2945 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pepinemab – Drug Profile

Product Description

Mechanism Of Action

History of Events

pridopidine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Rett Fusion Protein – Drug Profile

Product Description

Mechanism Of Action

Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

Rett Syndrome-MECP2 – Drug Profile

Product Description

Mechanism Of Action

RVL-001 – Drug Profile

Product Description

Mechanism Of Action

SHP-101 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize mGlu7 for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize Sigma-1 Receptor for Metabolic and Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit HDAC6 for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit PTP1B for Rett Syndrome – Drug Profile

Product Description

Mechanism Of Action

History of Events

STRX-230 – Drug Profile

Product Description

Mechanism Of Action

History of Events

tianeptine – Drug Profile

Product Description

Mechanism Of Action

History of Events

triheptanoin – Drug Profile

Product Description

Mechanism Of Action

History of Events

trofinetide – Drug Profile

Product Description

Mechanism Of Action

History of Events

TSHA-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TTI-0102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VYNT-0126 – Drug Profile

Product Description

Mechanism Of Action

Rett Syndrome – Dormant Projects

Rett Syndrome – Discontinued Products

Rett Syndrome – Product Development Milestones

Featured News & Press Releases

Jul 18, 2022: Acadia Pharmaceuticals submits New Drug Application to the U.S. FDA for Trofinetide for the treatment of Rett Syndrome

May 18, 2022: Neurogene announces new development program in Rett Syndrome utilizing novel EXACT technology platform

May 03, 2022: DepYmed receives FDA Rare Pediatric Disease and Orphan Drug Designations for its lead clinical candidate for the treatment of Rett Syndrome

Mar 29, 2022: Taysha Gene Therapies announces initiation of clinical development of TSHA-102 in Rett Syndrome

Mar 22, 2022: Acadia Pharmaceuticals to present late-breaking data at the 2022 American Academy of Neurology Annual Meeting (AAN)

Mar 10, 2022: DepYmed and Monash Biomedicine Discovery Institute to study the role of a new generation of PTP1B inhibitors against a novel intracellular checkpoint in cancer

Feb 04, 2022: Anavex life sciences provides supplemental information on ANAVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome

Feb 01, 2022: ANAVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints

Dec 07, 2021: Acadia reports positive data from Phase III Rett Syndrome drug trial

Dec 06, 2021: Acadia Pharmaceuticals announces positive top-line results from the pivotal phase 3 lavender trial of Trofinetide in rett syndrome

Sep 22, 2021: Taysha receives Orphan Drug Designation from the European Commission for TSHA-102 for the treatment of Rett Syndrome

Sep 08, 2021: Taysha Gene Therapies to host key opinion leader webinar on TSHA-102 for the treatment of Rett syndrome

Sep 01, 2021: DAFFODIL Rett syndrome clinical trial for trofinetide in girls aged 2 to 5 years

Aug 05, 2021: Rett syndrome Phase 3 trial enrolment successfully completed – results in Q4 2021

Jun 21, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Rett Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Rett Syndrome – Pipeline by 1st Bio Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Acadia Pharmaceuticals Inc, 2022

Rett Syndrome – Pipeline by Adge Pharmaceuticals Inc, 2022

Rett Syndrome – Pipeline by Alcyone Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Amicus Therapeutics Inc, 2022

Rett Syndrome – Pipeline by AMO Pharma Ltd, 2022

Rett Syndrome – Pipeline by Ananda Scientific Inc, 2022

Rett Syndrome – Pipeline by Anavex Life Sciences Corp, 2022

Rett Syndrome – Pipeline by ArmaGen Inc, 2022

Rett Syndrome – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Rett Syndrome – Pipeline by BioXcel Corp, 2022

Rett Syndrome – Pipeline by Connecta Therapeutics SL, 2022

Rett Syndrome – Pipeline by CuroNZ Ltd, 2022

Rett Syndrome – Pipeline by DepYmed Inc, 2022

Rett Syndrome – Pipeline by Echo Pharmaceuticals BV, 2022

Rett Syndrome – Pipeline by Epeius Pharma Co, 2022

Rett Syndrome – Pipeline by Epigen Biosciences Inc, 2022

Rett Syndrome – Pipeline by EuMentis Therapeutics Inc, 2022

Rett Syndrome – Pipeline by GEXVal Inc, 2022

Rett Syndrome – Pipeline by Herophilus, 2022

Rett Syndrome – Pipeline by Jazz Pharmaceuticals Plc, 2022

Rett Syndrome – Pipeline by LizarBio Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Lucy Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Neuren Pharmaceuticals Ltd, 2022

Rett Syndrome – Pipeline by Neurogene Inc, 2022

Rett Syndrome – Pipeline by Neurolixis Inc, 2022

Rett Syndrome – Pipeline by Novartis Gene Therapies, 2022

Rett Syndrome – Pipeline by OrganAI AB, 2022

Rett Syndrome – Pipeline by PharmatrophiX Inc, 2022

Rett Syndrome – Pipeline by Prilenia Therapeutics Development Ltd, 2022

Rett Syndrome – Pipeline by Q-State Biosciences Inc, 2022

Rett Syndrome – Pipeline by Sarepta Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Shape Therapeutics Inc, 2022

Rett Syndrome – Pipeline by Starwise Therapeutics LLC, 2022

Rett Syndrome – Pipeline by StrideBio Inc, 2022

Rett Syndrome – Pipeline by Synaptogenix Inc, 2022

Rett Syndrome – Pipeline by Taysha Gene Therapies Inc, 2022

Rett Syndrome – Pipeline by Thiogenesis Therapeutics SARL, 2022

Rett Syndrome – Pipeline by Ultragenyx Pharmaceutical Inc, 2022

Rett Syndrome – Pipeline by Unravel Biosciences, 2022

Rett Syndrome – Pipeline by Vaccinex Inc, 2022

Rett Syndrome – Pipeline by Vico Therapeutics BV, 2022

Rett Syndrome – Pipeline by Vyant Bio Inc, 2022

Rett Syndrome – Dormant Projects, 2022

Rett Syndrome – Dormant Projects, 2022 (Contd..1)

Rett Syndrome – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Rett Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.